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ABSTRACT
The present study aimed to assess the association of outcomes with comprehension, 
adherence and behavioral characteristics of tuberculosis (TB) patients using fixed-dose 
combination (FDC) therapy in the city of Contagem, MG, Brazil. This study used standardized 
questionnaires to collect data. Outcomes included cure in 77.2% (64/ 83), noncompliance 
with treatment in 20.4% (17/ 83), and absence of organ failure or death cases. The rate of 
adherence to treatment was high (71.1% - 59/ 83), while the level of comprehension of the 
treatment was insufficient for the majority of patients (72.3% - 60/ 83). When a greater 
number of medicines was used, the chance of noncompliance with treatment increased 
exponentially (p = 0.00 - OR 1.72). Light-skinned black patients, alcoholics and those who 
live with HIV/ AIDS showed a significant association with noncompliance with treatment 
(p=0.039 - OR 3.38, p=0.002 - OR 4.68, and p=0.001 - OR 9.68, respectively). Comprehension 
also presented a significant association with noncompliance with treatment (p=0.01 and OR 
5.76 and CI 1.49-22.29). The probability of noncompliance with treatment in the first few 
months was greater than in the subsequent months. This study demonstrates that if the TB 
patients had a better understanding of the treatment, the outcome would have been more 
favorable as regards a proper cure.
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INTRODUCTION
Tuberculosis (TB), considered a public health issue in its pulmonary clinical 
form, has been identified as the commonest form of new cases of the disease1. To 
confront this disease, one of the most important factors is an effective treatment. For 
this reason, Brazil has adopted procedures that aim to increase patients’ adherence 
and reduce patients’ noncompliance with treatment, thus increasing the cure rate 
of the disease2.
Patient noncompliance with TB treatment is a troublesome scenario and requires 
strategic measures to maintain a higher adherence to treatment3. Therefore, the 
success of the treatment depends heavily upon the proper embracement and follow-
up of the patients by healthcare professionals4.
The knowledge or comprehension of the disease is of great importance in 
treatment adherence. Adverse reactions to medications, the treatment regimen, as 
well as treatment costs for patients and their families can influence the outcome 
leading to a higher noncompliance4,5,6.
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In 2009, the National Program for the Control of 
Tuberculosis (NPCT), introduced ethambutol as the fourth 
drug in the first stage of the basic therapy. Ethambutol 
was added due to the increase in primary resistance to H4. 
There was a change in the pharmacological presentation 
of the schema, which began with FDC tablets containing 
four drugs - Rifampicin, Isoniazid, Pyrazinamide, and 
Ethambutol (RHZE) in the intensive stage2,8. The World 
Health Organization (WHO) also recommends the use of 
FDC to increase TB treatment adherence9,10.
The present study aimed to assess the association of 
outcomes with comprehension, adherence and behavioral 
characteristics of tuberculosis (TB) patients using FDC 
therapy in the city of Contagem, MG, Brazil. 
METHODS
This study was a prospective cohort aimed at evaluating 
the outcome of anti-TB treatment after the application of 
the new FDC (RHZE/ RH) drug therapy, conducted in 
Contagem, MG, Brazil. This study consisted of patients 
who were 18 years of age or older, with pulmonary or extra 
pulmonary TB, followed up at a primary care unit from 
November 2013 to April 2015, and defined as new cases. 
These patients were selected by the results registered in the 
TB laboratory information system or when they received 
the medicament to treat tuberculosis for the first time in 
regional pharmacies.
Patients submitted to retreatment outside the Primary 
Healthcare Unit (PHU) of Contagem, who died before the 
interview, were treated in other cities, and did not complete 
the treatment before the end of the study were excluded 
from this study.
The explanatory variables were collected by means 
of direct interviews conducted by the researcher using 
a standardized questionnaire. These variables included 
sociodemographic parameters (gender, age, education level) 
and socioeconomic characteristics (income); behavioral 
characteristics: use of illegal drugs; clinical characteristics 
(comorbidity); and Directly Observed Treatments (DOTS). 
To assess alcoholism, the CAGE (Cutdown, Annoyedby 
Criticism, Guilty and Eye-opener) questionnaire was 
applied11.
Morisky scale of adherence to treatment was adapted to 
assess the adherence of patients to TB treatment, which uses 
eight questions with “Yes” or “No” answers. A total score 
of eight is considered high adherence, a score of less than 
eight but higher than six is considered average adherence, 
and a score below six is considered low adherence12. This 
questionnaire, aimed at assessing comprehension, was 
adapted for TB, and the instrument used to assess the 
comprehension of treatment considers the answers sufficient 
when patients obtain 70% or more points and insufficient 
when the score is less than 70%5,13. This instrument was 
not applied to assess the comprehension of the use of other 
medicines, only to quantify them. This questionnaire was 
adapted from CIPOLLE to obtain the following variables: 
marital status, residency, smoking habits and side effects 
related to the drugs.14 All of the instruments were applied in 
three interviews during the patient’s treatment, the first one 
being conducted at the end of the first month, the second 
one at the end of the second month, and the third one at the 
end of the sixth month. 
The outcomes considered in this study included: cure, 
noncompliance with treatment, failure or death after the 
interview7,15.
The descriptive analysis with the frequency distribution 
was conducted with categorical variables. For continuous 
variables, the evaluation of the core and dispersion 
tendencies (median, average and standard deviation) were 
assessed using the Statistics Analysis Package, STATA 12.1. 
The magnitude of the association was estimated by means of 
the odds ratio (OR). For all of the analyses the significance 
level was p ≤ 0.05, with a confidence interval (CI) of 95%.
A logistic regression analysis was conducted in two 
stages. The first stage was a selection of the explicative 
variables with potential of association between each 
variable and the outcome. The first stage was done using 
a logistic regression with three variables, the outcome, the 
explicative variable tested and the moment at which there 
was noncompliance with the treatment between the first and 
second interview. For the association study, between the 
outcomes and the explanatory variables, two subjects which 
died before the interview were excluded, so the outcome 
became a dichotomic variable (cure/ noncompliance with 
treatment). This kind of procedure was a univariate logistic 
regression model controlled by moment. The variables with 
p-values equal to or greater than 0.20 in the Wald test, in the 
univariate controlled analysis, were manually selected to 
begin the multivariate analysis with a stepwise process, with 
a backward selection. The multivariate analysis was used 
to assess the association between the explicative variables 
and the outcome response variable: cure and noncompliance 
with treatment.
The adjustment of the Hosmer & Lemeshow model was 
also conducted. In this case, to demonstrate that the model 
was accepted, the null hypothesis should also be accepted, 
that is, p > 0.05.
This study was approved by the Research Ethics 
Committee from the Federal University of Minas 
Gerais (UFMG), under the protocol number CAAE 
16298413.0.0000.5149.
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RESULTS
Eighty-three (83) patients were included in this study 
(Figure 1), of which 59.0% (49/ 83) were male. Ages varied 
from 18 to 83 years, with an average age of 42.19 years 
(SD-15.0). The clinical form of TB was pulmonary in 84.3% 
(70/83) of the patients. The variables of sociodemographic, 
socioeconomic, behavioral and clinical characteristics, as 
well as those related to the drug therapy are in Table 1. Two 
patients were excluded because they did not complete the 
treatment before the end of the study.
The frequency of adherence to treatment was high 
(80.8% - 67/ 83). In 10.8% (9/ 83), the adherence was 
average, while in 8.4% (7/ 83) it was low (Table 1).
All patients presented side effects; however, the majority 
(97.5%) presented only a few reactions, and this variable 
had no effect on the patients’ noncompliance with treatment 
(Table 1).
Table 1 - Descriptive analysis of the sociodemographic behavioral, clinical and pharmacotherapeutic characteristics (n = 83)
Cured Noncom-pliance Death
N (%) N (%) N (%)
SOCIODEMOGRAPHIC
Age (> 18 years)
18 – 41 60(72.4) 10(12.0) 0
42 – 83 4(4.8) 7(8.4) 2(2.4)
(Average 42.19)
Gender
Male 39(47.0) 9(10.8) 1(1.2)
Female 26(31.3) 7(8.4) 1(1.2)
Housing
House /Apartment 63(75.9) 15(18.0) 2(2.4)
Shelter 1(1.2) 2(2.4) 0
Race
Light-skinned black 44(53.0) 15(18.1) 2(2.4)
Other races 20(24.1) 2(2.4) 0
Income
With Income 48(57.8) 10(12.1) 2(2.4)
Without Income 16(19.3) 7(8.4) 0
Education level
< 08 years 48(57.8) 13(15.7) 1(1.2)
> 08 years 16(19.3) 4(4.8) 1(1.2)
CLINICAL
Form
Pulmonary 52(62.7) 16(19.3) 2(2.4)
Extrapulmonary 12(14.4) 1(1.2) 0
Health problems
AIDS 5(6.0) 3(3.6) 0
Diabetes 7(8.4) 2(2.4) 0
Others 27(32.6) 5(6.0) 2(2.4)
No health problems 26(31.4) 6(7.2) 0
Cured Noncom-pliance Death
N (%) N (%) N (%)
TS/DOTS
Yes 9(10.8) 5(6.0) 0
No 55(66.3) 12(14.5) 2(2.4)
PHARMACOTHERAPEUTIC
Side effects
Lesser 64(77.1) 15(18.1) 2(2.4)
Greater 0 2(2.4) 0
Non-TB Medicines
Without use of medicines 25(30.1) 11(13.3) 0
01 medicine 13(15.7) 4(4.8) 0
02 medicines or more 24(28.9) 4(4.8) 2(2.4)
Adherence
High 51(61.5) 14(16.9) 2(2.4)
Average 9(10.8) 0 0
Low 4(4.8) 3(3.6) 0
Understanding
Sufficient 18(21.7) 3(3.6) 0
Insufficient 46(55.4) 14(16.9) 2(2.4)
BEHAVIORAL
Smoking
Yes 10(12.0) 5(6.0) 0
No 54(65.1) 12(14.5) 2(2.4)
Alcoholism
Yes 10(12.0) 6(7.2) 0
No 54(65.1) 11(13.3) 2(2.4)
Marital status
Single/Divorced/Widow 30(36.1) 10(12.1) 0
Married/Stable Union 34(41.0) 7(8.4) 2(2.4)
Figure 1 - Study sample
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Patients presented full cure in 77.2% (64/ 83) of the 
cases and noncompliance with treatment in 20.4% (17/ 83). 
There were no cases of organ failure or death caused by TB. 
Death after the interview by other causes was 2.4% (2/ 83).
Age, gender, marital status, education level, smoking 
habits, having a regular income or not and supervised 
treatment proved to be unassociated with patients’ 
noncompliance with treatment (Table 1).
The level of comprehension of TB treatment was 
insufficient for the majority of patients: 72.3% (60/ 83). 
The use of other medications in addition to anti-TB 
drugs happened in 56.6% (47/83). When the patient 
used a large number of medications the probability of 
noncompliance with treatment increased exponentially (OR 
1.72), with p=0.00 (Table 2).
Light-skinned black patients, alcoholics and those who 
live with HIV/ AIDS presented a significant association with 
the noncompliance with TB treatment (p=0.03, p = 0.00, 
and p=0.00, respectively). The parameter comprehension 
has also presented a significant association with the 
noncompliance with treatment (p=0.01, OR 5.76, and CI 
1.49-22.29), as shown in Table 2. 
Figure 2 shows that the probability of patients’ 
noncompliance with TB treatment in the first months 
is greater than in the subsequent months, and that the 
accumulated incidence was of 20.4% in the first two months. 
In 6.0% (5/ 83) of the patients who were noncompliant 
with the treatment, the noncompliance happened after the 
first interview, while in 10.8% (9/83) it happened after the 
second interview.
DISCUSSION
In 2003, Contagem was classified by the Brazilian 
Table 2 - Multivariate analysis of sociodemographic, behavioral, clinical and pharmacotherpeutic variables (n= 83)*
Variable/category Total 
n=83 (%) OR Crude OR Ajust CI P
Comprehension
Insufficient 60 (72.30) 8.00 5.76 1.49-22.29 0.01
Sufficient 23 (27.70)
Income
Without income 23 (27.70) 2.1 2.08 0.88-4.93 0.09
With income 60 (72.30)
Race
Light-skinned black 60 (72.30) 3.40 3.38 1.06-10.77 0.03
Other races 23 (27.70)
Smoking
Yes 15 (18.10) 2.25 1.52 0.60-3.85 0.38
No 68 (81.90)
Use of other non-anti-TB medicines
No use 36 (43.37)
01 medicine 17 (20.49) 1.63 1.72 1.44-2.06 0.00
02 medicines or more 30 (36.14) 2.78 2.94
Alcoholism
Yes 16 (19.30) 2.95 4.68 1.74-12.61 0.00
No 67 (80.70)
AIDS
Yes 8 (9.60) 2.53 9.68 2.63-35.70 0.00
No 75 (90.40)
*The model was controlled as of the beginning of the interview.
Figure 2 - Percentage of noncompliance with treatment 
according to the time of TB treatment
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Health Ministry (BHM) as a priority city in the number of 
TB cases7. In this city, the noncompliance with treatment 
is above that defined as acceptable by the WHO and the 
BHM, which is less than 5%4.
This study was conducted due to the change of TB 
treatment for FDC in 2009, considering that studies on the 
impact and outcome of new cases treated with FDC are 
scarce in the country.
The present study found that the cure rate was greater 
(77.2%) when compared to data from 2008 (prior to 
application) (69.1%), including all clinical forms; however, 
it has also proved to be quite inferior to that set forth by the 
WHO (85% cure rate for pulmonary TB cases)4. 
Noncompliance with treatment was similar (20.4%) 
to the data from 2008 (19.2%). The cure rate increased 
due to the reduction of deaths and organ failure, yet the 
noncompliance with treatment remained the same. Although 
other studies17,18,19 report similarities and divergences with 
the present study, none used primary data.
Although some sociodemographic, clinical and 
behavioral data in our study are not related to patients’ 
noncompliance with treatment, other studies have shown 
this relationship regarding age, gender, marital status, 
residency, education level, having a regular income or not, 
DOTS and smoking habit (Table 1)20,21,22,23. These studies 
used methods or analyses of results that were different from 
the ones used in the present study, which may well have 
generated divergences. In fact, the statistical analysis used 
in our study assessed the results considering the variables 
controlled by the moment of noncompliance with treatment 
between the first and second interviews regarding the 
parameter adherence, whose association with DOTS has 
been previously studied and demonstrated23,24.
FDC drug therapy is recommended by the WHO as 
an additional measure to increase patients’ adherence to 
TB treatment9,10; however, other studies report that this 
formulation is not related to the noncompliance with 
treatment17.
The insufficient level of comprehension presented a 
significant association with patients’ noncompliance with 
treatment. Therefore, it is necessary to invest in strategies that 
improve the quality of the guidelines provided to the patients. 
It is essential to encourage the communication of healthcare 
professionals with patients on an individual basis so that 
the patient will be able to understand the guidelines and 
the success of treatment. Note that the patients in this study 
received no incentives or any orientation about the disease. 
The medical advice provided by healthcare professionals 
concerning the medicines and their correct use must be a 
priority. In addition, comprehension of the difficulties and 
facilities that patients face to understand their treatment 
will help healthcare professionals to develop educational 
strategies aimed at the therapeutic process. The study 
showed that if the TB patients had understood the treatment 
the results could have been more favorable concerning 
their full cure.
Although no other studies have shown the association 
between the use of other medicines, other than those for 
TB, with patients’ noncompliance with treatment, in the 
present study, it was evident that each added medication 
increased the probability of noncompliance with treatment. 
However, some authors report that the association of various 
medicines interferes with the outcome25.
The side effects were the most commonly identified 
factor associated with noncompliance due to the method 
used in this study (interview), which shows the relevance 
and reliability of the information, given that the studies 
that reported only 20% and less side effects used secondary 
data and were not conducted with the entire population of 
a given city17.
The risk factors associated with noncompliance with 
treatment such as light-skinned blacks, alcoholics and 
patients who live with HIV/ AIDS, illustrate that these 
social and clinical questions are still important in an 
attempt to develop medical care actions geared toward 
these individuals, thus leading to TB control. Other authors 
have also observed this relationship as a predictor of 
noncompliance with treatment22.
As described by other authors22, the present study 
demonstrated that the probability of patients’ noncompliance 
with treatment, especially in the first two months, is 
greater, since the patient feels better, believes that 
he/she is cured and that there is no further need to continue 
taking the medicine. This reiterates the importance of the 
patient’s comprehension of the treatment. Thus, healthcare 
professionals should devote more time to the process of 
providing medical advice to patients, as well as in the follow 
up to guarantee all possible medical care to the patient. It 
is important to remember that these professionals should 
create ties with their patients so that the Health Unit can 
become a reference for these complications26.
The main limitation of this study was the lack of 
assessment of the comprehension and adherence to other 
medicines used to treat other medical conditions that could 
interfere in the results; however, this was not within the 
scope of this study.
It is therefore possible to conclude that the outcome of 
TB treatment after the application of the new FDC drug 
therapy in Contagem showed that the cure was below the 
recommended rate by WHO while noncompliance was 
above and that patients’ comprehension was associated with 
their noncompliance with treatment. 
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